Effects of Vadadustat on Anemia, Quality of Life, and Inflammation in Dialysis Patients

A Prospective Interventional Study Evaluating the Effects of Vadadustat on Anemia, Quality of Life, and Inflammatory Response in Dialysis Patients and Exploring Predictors of Treatment Response

This is a two-period, two-sequence crossover study in patients receiving maintenance peritoneal dialysis. All participants remain on background darbepoetin alfa therapy throughout the study. The study compares add-on vadadustat plus background darbepoetin alfa with background darbepoetin alfa alone, with each treatment period lasting 8 weeks and separated by a 4-week washout period. Monthly laboratory assessments and dialysis adequacy measurements will be performed to evaluate anemia control, quality of life, inflammation, and dialysis adequacy.

Inclusion Criteria:

• Age 18 years or older
• Receiving maintenance peritoneal dialysis
• Followed at the outpatient clinics of MacKay Memorial Hospital
• Receiving background darbepoetin alfa therapy
• Able and willing to provide informed consent

Exclusion Criteria:

• Blood pressure >170/80 mmHg on three separate occasions
• Recent cardiovascular events within the past 3 months, including coronary artery disease, myocardial ischemia, cerebrovascular disease, or peripheral artery disease
• Gastrointestinal bleeding within the past 3 months
• Active malignancy